Practical consensus recommendaton for adjuvant bone-modifying agents in breast cancer

A Bharatuar, M Kar, S Khatri, V Goswami, R Sarin, S Dawood, R Iyenger, M Ganvir, Purvish M Parikh, S Aggarwal, Vineet Talwar

South Asian Journal of Cancer 2018 7(2):91-95

Bone-modifying therapy is a primary research interest in breast cancer. Several features contribute to the importance of the bone environment in the management of breast cancer. Firstly, bone metastases represent the most common site of breast cancer metastases and secondly, the emergence of cancer treatment-induced bone loss (CTIBL) among breast cancer survivors and patients is of increasing concern. In the adjuvant setting, bisphosphonates can be given to prevent and treat tumor therapy-induced bone loss in premenopausal and postmenopausal women and, owing to their beneficial effect on bone turnover, have also been evaluated for prevention of bone metastases occurrence. Expert oncologists discusses on the update on the approaches of Bone-modifying Agents and its treatment options. This expert group used data from published literature, practical experience and opinion of a large group of academic oncologists to arrive at this practical consensus recommendations for the benefit of community oncologists.

https://ift.tt/2qyvyAd